Obagi Skintrinsiq Clarifiying Protocol Kit
NDC 62032-909
Product Information
Obagi Skintrinsiq Clarifiying Protocol (salicylic acid, titanium dioxide, and zinc oxide) is a OTC MONOGRAPH DRUG-approved product labeled by Obagi Cosmeceuticals Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a kit. This product entry covers the primary NDC 62032-909 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 62032-909?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SALICYLIC ACID (UNII: O414PZ4LPZ)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (Active Moiety)
- ZINC OXIDE (UNII: SOI2LOH54Z)
- ZINC OXIDE (UNII: SOI2LOH54Z) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- 3-((L-MENTHYL)OXY)PROPANE-1,2-DIOL (UNII: KD6TZ2QICH)
- ALCOHOL (UNII: 3K9958V90M)
- BENZYL ALCOHOL (UNII: LKG8494WBH)
- CHAMOMILE (UNII: FGL3685T2X)
- DIETHYLENE GLYCOL MONOETHYL ETHER (UNII: A1A1I8X02B)
- EXT. D&C VIOLET NO. 2 (UNII: G5UX3K0728)
- GLYCERIN (UNII: PDC6A3C0OX)
- MENTHOL, UNSPECIFIED FORM (UNII: L7T10EIP3A)
- MENTHYL LACTATE, (-)- (UNII: 2BF9E65L7I)
- WATER (UNII: 059QF0KO0R)
- ALUMINUM OXIDE (UNII: LMI26O6933)
- CAPRYLHYDROXAMIC ACID (UNII: UPY805K99W)
- CAPRYLYL GLYCOL (UNII: 00YIU5438U)
- CETEARYL GLUCOSIDE (UNII: 09FUA47KNA)
- CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)
- DICAPRYLYL CARBONATE (UNII: 609A3V1SUA)
- GLYCYRRHIZINATE DIPOTASSIUM (UNII: CA2Y0FE3FX)
- MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)
- PENTYLENE GLYCOL (UNII: 50C1307PZG)
- POLYHYDROXYSTEARIC ACID (2300 MW) (UNII: YXH47AOU0F)
- PROPANEDIOL (UNII: 5965N8W85T)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- SODIUM STEAROYL GLUTAMATE (UNII: 65A9F4P024)
- STEARETH-2 (UNII: V56DFE46J5)
- STEARETH-21 (UNII: 53J3F32P58)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TRIETHOXYCAPRYLYLSILANE (UNII: LDC331P08E)
- TRISODIUM ETHYLENEDIAMINE DISUCCINATE (UNII: YA22H34H9Q)
- TROPAEOLUM MAJUS FLOWERING TOP (UNII: RGT30824HY)
- XANTHAN GUM (UNII: TTV12P4NEE)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1235208 - CLENZIderm M.D. 2 % Pore Therapy Topical Solution
- RxCUI: 1235208 - salicylic acid 20 MG/ML Topical Solution [Clenziderm]
- RxCUI: 1235208 - Clenziderm 20 MG/ML Topical Solution
- RxCUI: 1235208 - Clenziderm M.D. 2 % Pore Therapy
- RxCUI: 251577 - salicylic acid 2 % Topical Solution
* Please review the full disclaimer at the bottom of this page.